OLEARY DENISE M
Known title: DirectorCIK: 0001145159
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
MiniMed completes separation from Medtronic. Medtronic has finalized the separation of its MiniMed insulin pump business, which is now operating as an independent company with a new board of directors. This corporate restructuring marks a significant shift in Medtronic's portfolio structure. Meanwhile, the company was named to the TIME Best Inventions of 2026 list for its Stealth AXiS surgical system and Corsano wearable, highlighting continued innovation in its remaining product lines.
Transaction History
| AAL | ▲ Buy | Grant | 13,562 | $0 | 6/11/2025 | View on chart |
| AAL | ▲ Buy | Grant | 12,908 | $0 | 6/5/2024 | View on chart |
| MDT | ▼ Sell | Tax Withholding | 192 | $16K | 5/1/2024 | View on chart |
| MDT | ▲ Buy | Grant | 2,165 | $175K | 4/29/2024 | View on chart |
| AAL | ▲ Buy | Grant | 10,460 | $0 | 5/10/2023 | View on chart |
| MDT | ▼ Sell | Tax Withholding | 169 | $15K | 5/2/2023 | View on chart |
| MDT | ▲ Buy | Grant | 1,930 | $175K | 5/1/2023 | View on chart |
| AAL | ▲ Buy | Grant | 9,287 | $0 | 6/8/2022 | View on chart |
| MDT | ▼ Sell | Tax Withholding | 262 | $27K | 5/3/2022 | View on chart |
| MDT | ▲ Buy | Grant | 1,697 | $0 | 5/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Analysts Lower AAL Fair Value Amid Rising Fuel Cost Concerns
Analysts have lowered American Airlines’ fair value after reexamining fuel cost assumptions. The recent Goldman Sachs cut to an $11 target reflects the same concern. New regulatory pressure to carry epinephrine on all flights could add to operating costs, while broader airline earnings reports from Delta give context to the sector’s mixed outlook.
Analysts Lower AAL Fair Value Amid Rising Fuel Cost Concerns. Analysts have lowered American Airlines’ fair value after reexamining fuel cost assumptions. The recent Goldman Sachs cut to an $11 target reflects the same concern. New regulatory pressure to carry epinephrine on all flights could add to operating costs, while broader airline earnings reports from Delta give context to the sector’s mixed outlook.